IM
IMNM
Stock Immunome Inc.Methodology breakdown computing — it will appear here on its own.
Immunome Inc (IMNM) is currently considered not halal (non-compliant), per our secondary compliance provider (last assessed 2026-08-25). See the full ratio breakdown and business-activity screen below for the reasoning.
⚠️ Financial ratios are only half the screen. A company whose core business is in an excluded sector — weapons/defense, alcohol, gambling, conventional (interest-based) finance, tobacco, pork, or adult entertainment — is non-compliant even if every debt and income ratio passes. So passing ratios below don't override this verdict; check the business-activity screen for the reason.
🕌 In-house Compliance Research
Computing the full ratio and business-activity breakdown for IMNM — this runs off the critical path so the page paints first. It will appear here on its own.
Pinch or scroll to zoom · drag to pan — both axes move · double-click to reset
Classic floor-trader pivots from the last completed daily bar. Highlighted pills are the levels bracketing the current price.
Price Forecast
The range is measured volatility (ATR over the horizon), not a target — a wider band means a more volatile asset, not a stronger view. The direction is the indicator tally above. Every forecast is recorded when made and scored against the real price when it comes due, including the wrong ones. Not a recommendation, and not a fatwa.
Technical Summary
Every indicator, and what it reads
| Indicator | Value | Signal |
|---|---|---|
| RSI (14) | 39.30 | NEUTRAL |
| Stochastic %K (14) | 1.37 | BUY |
| CCI (20) | -182.30 | BUY |
| Williams %R (14) | -98.63 | BUY |
| MACD (12,26,9) | -0.55 | SELL |
| ROC (10) | -14.55 | SELL |
| Momentum (10) | -4.20 | SELL |
| EMA (10) | 26.35 | SELL |
| SMA (10) | 26.59 | SELL |
| EMA (20) | 26.59 | SELL |
| SMA (20) | 27.47 | SELL |
| EMA (30) | 26.24 | SELL |
| SMA (30) | 26.77 | SELL |
| EMA (50) | 25.37 | SELL |
| SMA (50) | 25.27 | SELL |
| EMA (100) | 23.84 | BUY |
| SMA (100) | 23.17 | BUY |
| EMA (200) | 22.00 | BUY |
| SMA (200) | 22.48 | BUY |
Standard indicator thresholds (RSI 30/70, Stochastic 20/80, CCI ±100, Williams %R −80/−20, MACD histogram sign, price vs. average) computed on daily bars. A summary of what common indicators say — not a recommendation, and not this site's own trading verdict.
About Immunome Inc
Healthcare · Biotechnology
Immunome, Inc., a biotechnology company, engages in the discovery, design, development, manufacturing, and commercialization of antibody-drug conjugates and other oncology therapeutics in the United States. The company develops clinical asset comprising Varegacestat, a gamma secretase inhibitor that is in Phase 3 clinical trial for the treatment of desmoid tumors; and IM-1021, a receptor tyrosine kinase-like orphan receptor 1 antibody-drug conjugate (ADC), which is in Phase 1 clinical trial. It is also developing preclinical assets, including IM-3050, a fibroblast activation protein targeted radioligand therapy; and solid tumor ADC drug candidates, such as IM-1617, IM-1340, and IM-1335. Immunome, Inc. was incorporated in 2006 and is based in Bothell, Washington.
Background via Yahoo Finance — informational, not part of the verdict.
Average — needs more confirmation before sizing up
SMC — Top Down
| Timeframe | Bias | Bars |
|---|---|---|
| 📅 Daily | BEARISH | 43 |
| ⏰ 4H | BEARISH | 38 |
| 🕐 1H | BEARISH | 98 |
| ⏱ 15-Min | BEARISH | 130 |
| ⏲ 5-Min | BEARISH | 234 |
Momentum & Volume
Peer Movement
Peer movement computing — it will appear here on its own.
Insider Activity (90d)
CLUSTER SELL 0 buys · 13 sells
Recent: Barchas Isaac sold 308504 sh @ $21.12 (2026-06-30); Barchas Isaac sold 232839 sh @ $22.35 (2026-07-02); Barchas Isaac sold 208504 sh @ $23.33 (2026-07-02)
COT Positioning — E-MINI S&P 500 - CHICAGO MERCANTILE EXCHANGE
NEUTRAL report date 2026-09-08 · Asset managers net 912361 (-21819)
AI Summary
Plain-language summary of the evidence already on this page — the Sharia screen, structure, momentum, and order flow above. It explains the read; it doesn't make the call. Generated on demand (a live AI call), never run automatically.